Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)
-
![Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine) structure](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220812/91693a77dc71443497454aa14fdfc42a.png "Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)")
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)
structure -
-
CAS No:
457071-73-7
-
Formula:
C29H41NO4
-
Chemical Name:
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)
-
Synonyms:
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine);N-(3-Butenyl)norbuprenorphine;Buprenorphine Related CoMpound A CII;Buprenorphine Related Compound A CII (25 mg) ((S)-2-[17-(But-3-en-1-yl)-4,5alpha-epoxy-3-hydroxy-6-methoxy-6alpha,14-ethanomorphinan-7alpha-yl]- 3,3-dimethylbutan-2-ol)
-
CAS No:
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine) Basic Attributes
467.64014
467.304
FK1305SA1B
DTXSID70196606
2939110000
Safety Information
P261, P264, P270, P271, P285, P301+P312, P304+P312, P304+P340, P304+P341, P312, P330, P342+P311, P501
H302
|Danger|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P285, P301+P312, P304+P312, P304+P340, P304+P341, P312, P330, P342+P311, and P501|Aggregated GHS information provided by 3 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine) Use and Manufacturing
An impurity in the synthesis of Buprenorphine (B689570), which is a controllled substance (narcotic). Analgesic that demonstrates narcotic agonist-antagonist properties.
Computed Properties
Molecular Weight:467.6
XLogP3:5.3
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:6
Exact Mass:467.30355879
Monoisotopic Mass:467.30355879
Topological Polar Surface Area:62.2
Heavy Atom Count:34
Complexity:856
Defined Atom Stereocenter Count:7
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Learn More Other Chemicals
-
Cefdinir Related Compound A (10 mg) (2(R)-2-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-2-[(2RS,5RS)-5-methyl-7-oxo-2,4,5,7-tetrahydro-1Hfuro[3,4-d][1,3]thiazin-2-yl]acetic acid)
178422-42-9
-
Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)
30806-86-1
-
Bupropion Hydrochloride Related Compound A (15 mg) (2-(tert-butylamino)-4'-chloropropiophenone hydrochloride)
1049718-72-0
-
Trimethoprim Related Compound A (25 mg) (4-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol) (AS) Formula
60729-91-1
-
Proguanil Related Compound D (25 mg) (1,5-bis(1-methylethyl)biguanide hydrochloride) Formula
35708-82-8
-
Ethambutol Related Compound A (15 mg) ((2R,2'S)-2,2'-[ethane-1,2-diylbis(azanediyl)]dibutan-1-ol) Formula
10054-06-5
-
Tacrolimus Related Compound A (15 mg) (See USP Certificate for full Chemical Name) Structure
135635-46-0
-
NIMODIPINE RELATED COMPOUND A (50 MG) (2-METHOXYETHYL1-METHYLETHYL 2,6-DIMETHYL-4-(3-NITROPHENYL)PYRIDINE-3,5-DICARBOXYLATE) Structure
85677-93-6
-
What is HALOPERIDOL RELATED COMPOUND A (15 MG) (4,4'-BIS[(4-P-CHLOROPHENYL)-4-HYDROXY-PIPERIDINO]-BU-TYROPHENONE)
67987-08-0
-
What is Dantrolene Related Compound A (50 mg) (5-(4-nitrophenyl)-2-furaldehyde azine)
301359-05-7
Buprenorphine Related Compound A CII (25 mg) (21-[3-(1-Propenyl)]-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine)
SDSRequest for Quotation